Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
54.090USD
+1.000+1.88%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
5.19BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of CRISPR Therapeutics AG is 7.48, ranking 293 out of 389 in the Biotechnology & Medical Research industry. The average price target is 74.50, with a high of 268.00 and a low of 32.00.
Analyst Rating
Based on
26
analysts
Buy
Current Rating
80.672
Target Price
+49.14%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
CRISPR Therapeutics AG
CRSP
26
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is CRISPR Therapeutics AG's expected revenue for the next quarter?
CRISPR Therapeutics AG's expected revenue is 6.18M.
What is CRISPR Therapeutics AG's price target?
Analysts forecast that CRISPR Therapeutics AG's price target is USD 74.50, with the highest forecast at USD 268.00 and the lowest forecast at USD 32.00.
How have CRISPR Therapeutics AGCRSP's recent earnings per share performed?
The market expectation was USD -1.28, while CRISPR Therapeutics AGCRSP's earnings per share (EPS) for the previous quarter was USD -1.37. EPS for the next quarter is expected at USD -1.19.
What is the analyst rating for CRISPR Therapeutics AG?
Based on the ratings of CRISPR Therapeutics AG's stock from 26 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
